An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Chronic pain is nowadays considered not only the mainstay symptom of rheumatic diseases
but also “a disease itself.” Pain is a multidimensional phenomenon, and in inflammatory …

Chronic pain syndrome is a heterogeneous group of diseases characterized by several
pathological mechanisms. One in five adults in Europe may experience chronic pain. In …

Janus kinase family (JAKs) has recently attracted the attention of many researchers, and
several JAK inhibitor drugs have been developed targeting different members of the JAK …

Introduction: Alopecia is often a cause of great concern to patients for cosmetic and
psychologic reasons. The aim of treating non-scarring alopecias is to reduce hair loss and …

Objectives Small molecule tyrosine kinase inhibitors [smTKI, comprising mostly of Janus
kinase (JAK) and to a lesser extent, spleen tyrosine kinase (SyK) inhibitors] modulate the …

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation and
destruction of the joints as well as an increased risk of cardiovascular disease. RA synovial …

Background Biologic disease‐modifying anti‐rheumatic drugs (biologics) are highly effective
in treating rheumatoid arthritis (RA), however there are few head‐to‐head biologic …

Tofacitinib is a Janus kinase 3 (JAK3) inhibitor that promotes hair growth; however, the
efficacy and mechanism of this effect are not yet understood. This study aimed to evaluate …

Introduction The aim of this study was to describe the real-world evidence for effectiveness,
treatment persistence, and treatment patterns among patients in the community with …